In tumour centers, the number of tru-cut biopsies performed are increasing over open biopsies in recent years. In this study, we investigated the reliability of tru-cut biopsies based on the experience of 355 cases. According to first tru-cut biopsy results, 135 of the cases were sarcomas, 96 were benign tumours, 48 were non-tumoral lesions, 22 were fibromatosis, 20 were metastases, and 2 were lymphomas. Material was insufficient in 6% of the tru-cut biopsies. Of the cases, 162 resection material were evaluated, malignant fibrous histiocytoma (25%) and liposarcoma were the most frequent sarcomas among 103 primary malignant tumour. Diagnostic accuracy for malignancy was 97%, for the diagnosis of sarcoma sensitivity was 90% accuracy was 94%, sensitivity for grading was 88%, sensitivity for subtyping of sarcomas was 86% with tru-cut biopsy. In conclusion, these findings which are parallel to literature show that tru-cut biopsy is a reliable tool and it may be use instead of open biopsy. But it is good to be cautious while evaluating the tru-cut biopsy because it is difficult to get experience in relatively rare soft tissue tumours. We believe that one should not hesitate to request a rebiopsy or open biopsy if there is any suspicion in evaluating the tru-cut biopsy especially for the points that may cause major changes in the treatment planning such as differential diagnosis between sarcoma and lymphoma or metastasis, and histological grading. On the other hand we think that clinicopathological correlation will decrease possibility of misinterpretation.